Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,015 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, Nanda I, Weigand I, Gehrig A, Steinhauer S, Riemens RJM, Rosenwald A, Müller CR, Kroiss M, Rost S, Fassnacht M, Ronchi CL. Lippert J, et al. Among authors: liang r. J Clin Endocrinol Metab. 2018 Dec 1;103(12):4511-4523. doi: 10.1210/jc.2018-01348. J Clin Endocrinol Metab. 2018. PMID: 30113656
PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma.
Warmington E, Smith G, Chortis V, Liang R, Lippert J, Steinhauer S, Landwehr LS, Hantel C, Kiseljak-Vassiliades K, Wierman ME, Altieri B, Foster PA, Ronchi CL. Warmington E, et al. Among authors: liang r. Endocr Connect. 2023 Dec 14;13(1):e230403. doi: 10.1530/EC-23-0403. Print 2024 Jan 1. Endocr Connect. 2023. PMID: 37992487 Free PMC article.
Chemically engineered antibodies for autophagy-based receptor degradation.
Cheng B, Li M, Zheng J, Liang J, Li Y, Liang R, Tian H, Zhou Z, Ding L, Ren J, Shi W, Zhou W, Hu H, Meng L, Liu K, Cai L, Shao X, Fang L, Li H. Cheng B, et al. Among authors: liang r. Nat Chem Biol. 2025 Jan 9. doi: 10.1038/s41589-024-01803-1. Online ahead of print. Nat Chem Biol. 2025. PMID: 39789191
Phase 2 pilot trial of tislelizumab plus low-dose nab-paclitaxel for extensive very high-risk non-muscle-invasive bladder cancer.
Qie Y, Huang S, Shen C, Wu Z, Da L, Jia K, Zhang Z, Zhao G, Wang L, Xu G, Zhao Y, Liang R, Guo J, Li C, Dong H, Li M, Li H, Chen H, Tian D, Wu C, Zhang W, An Z, Wang H, Niu Y, Hu H. Qie Y, et al. Among authors: liang r. Clin Cancer Res. 2025 Jan 7. doi: 10.1158/1078-0432.CCR-24-3321. Online ahead of print. Clin Cancer Res. 2025. PMID: 39777450
4,015 results